@WHO: The Technical Advisory Group expects to receive these clarifications from the manufacturer (Bharat Biotech) by the end of this week, and aims to reconvene for the final risk-benefit assessment on Wednesday, 3 November 2021. #Covaxin #COVID19

http://twitter.com/WHO
via IFTTT